About us
Building on Solid Achievements, Dedicated to improving sepsis diagnosis and treatment
Sepsis is responsible for approximately 48,000 deaths annually in the UK alone and represents a multi-billion-dollar global diagnostics market. Despite this, current testing remains non-specific, often leading to delayed or misdirected treatment. There is a clear unmet need for better tools to help clinicians identify patients at risk of severe sepsis earlier and prioritise treatment appropriately.
MicrosensDx, a diagnostics company, is addressing the profound unmet clinical need to diagnose sepsis more specifically and enable targeted treatment sooner. Based on the company’s IP, its pioneer product, the ox-PTX3 test, is a novel blood test for sepsis, which measures specific forms of pentraxin (PTX3) and can be used to diagnose sepsis, risk profile patients and monitor treatment. Its ‘dual-sensor’ approach provides unique insights that current tests cannot.
With a strong record of commercialising inventions, MicrosensDx’s IP portfolio expands from sepsis to sample preparation and protein aggregation. The company applies its substantive experience in developing diagnostics to make improvements in healthcare both possible and universally deployable.
Empowering Diagnostic Testing and Providing Insights into Sepsis Prognosis
Note: Products are in development, please contact us for more information and to discuss collaboration opportunities. Disclaimer
We are driven by delivering high quality products which are based on the requirements of patients, clinicians and clinical laboratory professionals. This means that we provide what is needed from a performance point of view but also ensuring ease of use to allow a fast streamlined workflow.
Our Company values are based on trust, mutual respect, providing choice, collaboration and scientific excellence thus ensuring confidence in the results delivered by our products.